{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:54:49Z","timestamp":1786719289617,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101639"],"award-info":[{"award-number":["82101639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with high recurrence rates and poor survival outcomes. Growing evidence suggests that systemic inflammation plays a critical role in tumor progression and immune evasion. The pan-immune-inflammation value (PIV), a composite index derived from peripheral blood counts, has emerged as a potential biomarker of host immune and inflammatory status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate the prognostic value of preoperative PIV in Chinese cases with TNBC following curative surgical resection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cohort study of 312 TNBC cases treated at a tertiary center in China between January 2015 and March 2020. PIV was calculated as (neutrophil count\u2009\u00d7\u2009platelet count\u2009\u00d7\u2009monocyte count)\/lymphocyte count using preoperative blood tests. According to a ROC-derived cutoff value of 353, cases were stratified into low and high PIV groups. Kaplan\u2013Meier curves and Cox regression analyses were used to analyze survival outcomes, like disease-free survival (DFS) and overall survival (OS). Confounders for multivariate adjustment were selected based on clinical relevance and univariate significance (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.10). Model performance was evaluated using Harrell's concordance index (C-index).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cases with a high PIV showed significantly worse survival outcomes. The 5-year OS was 62.5% in the high PIV group compared with 71.6% in the low PIV group. High PIV was also associated with shorter DFS (median 36.8 vs. 45.2 months, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Multivariate analysis confirmed high PIV as an independent predictor of poor OS (HR, 1.75; <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and DFS (HR, 1.61; <jats:italic>p<\/jats:italic>\u2009=\u20090.009), even after adjusting for tumor stage, nodal status, and histologic grade.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Preoperative PIV is an independent and accessible prognostic biomarker in Chinese cases with TNBC following surgery. Its integration into clinical risk models may aid in identifying high-risk cases and tailoring postoperative management strategies for them.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2025.1636235","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:29:11Z","timestamp":1760419751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of pan-immune-inflammation index in the prognosis of Chinese cases with triple-negative breast cancer following surgical resection"],"prefix":"10.3389","volume":"12","author":[{"given":"Ming","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuele","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/ph14101008","article-title":"Molecular targets and promising therapeutics of triple-negative breast cancer","volume":"14","author":"Ryu","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.currproblcancer.2022.100866","article-title":"Prognostic factors and survival according to tumor subtype in women with breast cancer brain metastases","volume":"46","author":"Lopes","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"104417","DOI":"10.1016\/j.critrevonc.2024.104417","article-title":"Next-generation biomarkers for prognostic and potential therapeutic enhancement in triple negative breast cancer","volume":"201","author":"Banerjee","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"106939","DOI":"10.1016\/j.intimp.2020.106939","article-title":"Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment","volume":"88","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3390\/ijms26062716","article-title":"The role of the tumor microenvironment (TME) in advancing cancer therapies: immune system interactions, tumor-infiltrating lymphocytes (TILs), and the role of exosomes and inflammasomes","volume":"26","author":"Erasha","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1093\/oncolo\/oyad303","article-title":"Development of a prognostic model for early breast cancer integrating neutrophil to lymphocyte ratio and clinical-pathological characteristics","volume":"29","author":"Faria","year":"2024","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41416-020-0894-7","article-title":"The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials","volume":"123","author":"Fuc\u00e0","year":"2020","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"996844","DOI":"10.3389\/fsurg.2022.996844","article-title":"Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-024-00635-x","article-title":"LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer","volume":"25","author":"Pan","year":"2024","journal-title":"BMC Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e70072","DOI":"10.1111\/1759-7714.70072","article-title":"Current status of immune checkpoint inhibitors and treatment responsive biomarkers for triple-negative breast cancer","volume":"16","author":"Wang","year":"2025","journal-title":"Thorac Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/AS9.0000000000000113","article-title":"Pan-immune-inflammation value and prognosis in patients with esophageal cancer","volume":"3","author":"Baba","year":"2022","journal-title":"Ann Surg Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.2147\/JIR.S468537","article-title":"The baseline pan-immune-inflammation value (PIV) and PILE in predicting clinical outcomes and therapeutic response for primary central nervous system lymphoma","volume":"17","author":"Duan","year":"2024","journal-title":"J Inflamm Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11517","DOI":"10.1038\/s41598-025-96592-5","article-title":"Preoperative pan-immuno-inflammatory values and albumin-to-globulin ratio predict the prognosis of stage I\u2013III colorectal cancer","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6036979","DOI":"10.1155\/2019\/6036979","article-title":"Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer","volume":"2019","author":"Stojkovic Lalosevic","year":"2019","journal-title":"Dis Markers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17588359231165978","DOI":"10.1177\/17588359231165978","article-title":"The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis","volume":"15","author":"Provenzano","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"115015","DOI":"10.1016\/j.biopha.2023.115015","article-title":"Evaluation of the association of chronic inflammation and cancer: insights and implications","volume":"164","author":"Nigam","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cancers14112675","article-title":"The association between the pan-immune-inflammation value and cancer prognosis: a systematic review and meta-analysis","volume":"14","author":"Guven","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1507371","DOI":"10.3389\/fimmu.2024.1507371","article-title":"Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features","volume":"15","author":"Boissi\u00e8re-Michot","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1492251","DOI":"10.3389\/fonc.2024.1492251","article-title":"Prognostic significance of systemic pan-immune-inflammation value in locally advanced cervical cancer","volume":"14","author":"Yan","year":"2024","journal-title":"Front Oncol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1636235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:29:12Z","timestamp":1760419752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1636235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":20,"alternative-id":["10.3389\/fsurg.2025.1636235"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2025.1636235","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1636235"}}